AlzProtect brings together experts in neurodegeneration and confirmed skills in pharmaceutical and clinical development, as well as experienced managers from the pharmaceutical industry.

Executive Board

Philippe Verwaerde

Philippe Verwaerde

PhD
Chief Executive Officer / Chief Scientific Officer

Philippe Verwaerde has 33 years of international experience (USA, FR, BE, IT, SW) in the pharmaceutical industry, at Organon, GlaxoWellcome and Biovitrum. He also has been involved in biotech companies, including DevGen and Genfit.
He is the co-founder of Vivactis and iNovacia, a Swedish company of pharmaceutical services, as vice-president of Molecular Pharmacology.

Noëlle Callizot

Noëlle Callizot

PharmD, PhD
Director of Pharmaceutical Development

For 20 years, she has enabled the pharmaceutical development of neuroactive molecules up to advanced clinical stage. During her 6 years as director of neuropharmacology at Phytopharm (UK), she has led various programs in neurodegenerative diseases (Alzheimer’s and Parkinson’s) up to phase 3.
Noëlle Callizot is the co-founder of 4 biotech companies in the fields of contract research, functional neuro-habilitation, screening and neuroactive molecules. President of the AFM-TELETHON Pharma Commission, Noëlle Callizot also chairs several strategic programs for the AFM.

Project team

Cecilia Estrella

Cecilia Estrella

PhD
Pharmacology Manager, Senior Pharmacologist

24 years of experience in Neuroscience and Neuroendocrinology research at international laboratories (SP, AG) and in France (INSERM, University of Lille and Pasteur Institute in Lille).

Stéphane Burlet

Stéphane Burlet

PhD
Regulatory Pre-clinical Development & Chemistry Manager

Stéphane has 20 years of experience in pharmaceutical and biotech companies (Trophos, HMR/Aventis Sanofi).

Cyrille Brantis

Cyrille Brantis

Engineer
Intellectual Property Manager

Cyrille has 19 years of international experience in biotech companies (UK, BE) and IP firm.

Nathalie Faltraue

Nathalie Faltraue

Executive Assistant

Nathalie has over 25 years of experience in administrative management, accounting and human resources.

Board of Directors

François-René Letourneur

François-René Letourneur

Chairman of the Board of Directors at Finovam, François-René Letourneur is a very experienced venture capital investor and manager.
His expertise covers multiple high-tech sectors and the management of international fast-growing companies.

Pierre Le Sourd

Pierre Le Sourd

MD, Cardiologist,
Columbia University Graduate

Pierre Le Sourd has been the Chair of Specia Laboratories, of the group Juveinal, then Bristol-Myers Squibb France and the group UPSA.
He has also served as a Chair for Leem (Les Entreprises du Médicament) and as a Vice-Chair for the French Federation of Health industries (Fédération Française des Industries de Santé, FEFIS).
He is currently Chief Financial Officer at XERYS, Director of ABCD Innovation, and Treasurer of the Automobile Club Médical in France.
He contributes to AlzProtect with his excellent knowledge of pharmaceutical markets, with both a medical and an industrial approach.

Pierre Besançon

Pierre Besançon

Pierre Besançon, previously a Professor in Pharmacy, is the successor to former Laboratoires Delagrange. He is an experienced private investor in the field of biotech companies both in Europe and in the United States.

Jacqueline Lecourtier

Jacqueline Lecourtier

Jacqueline Lecourtier is a graduate in chemical engineering and made her professional debut at the CNRS as a research fellow. She then joined the French Petroleum Institute (Institut Français du Pétrole, IFP) as a scientific director.
Former CEO of the French National Research Agency (Agence Nationale de la Recherche, ANR), she currently acts as a Corporate Director for chemical industry companies: Carbios, Optimum Hydrocarbon Technologies, and PCAS, a French chemical group.
Her strategic approach of research and her industrial experience are valuable for the development of AlzProtect.

Philippe Verwaerde

Philippe Verwaerde

Président d’AlzProtect

 

Scientific Advisory Board

Professeur Philippe Amouyel

Philippe Amouyel

MD, PhD

A former medical intern, Philippe Amouyel is a Professor of Epidemiology and Public Health at the University Hospital of Lille. Since 1998, he has been the director of the mixed research unit Inserm - University of Lille 2 – Lille Pasteur Institute, dedicated to public health and molecular epidemiology of aging-related diseases at the Pasteur Institute campus in Lille.

Professeur Luc Buée

Luc Buée

PhD

CNRS Research Director, Head of the Jean-Pierre Aubert Center Laboratory “Alzheimer & Tauopathies” at the University of Lille (France). His research activities have been focusing on Alzheimer’s disease and related syndromes for over 20 years. Luc Buée is also involved in various scientific advisory boards: Fondation de France Parkinson, Fédération pour la Recherche sur le Cerveau and the Alzheimer’s Drug Discovery Foundation (ADDF, NY, USA). In 2006-2007, he participated in the Inserm collective expertise on Alzheimer’s disease and after the Alzheimer Plan was published in February 2008, he was appointed to the operations committee of the Fondation Plan Alzheimer.

Professeur Florence Pasquier

Florence Pasquier

MD, PhD

Florence Pasquier, Professor of Neurology and Director of the Center of Memory at Lille University Hospital, is recognized worldwide for her expertise in the field of clinical trials on Alzheimer’s disease.

Professeur Thomas Bayer

Thomas Bayer

PhD

Florence Pasquier, Professor of Neurology and Director of the Center of Memory at Lille University Hospital, is recognized worldwide for her expertise in the field of clinical trials on Alzheimer’s disease.